Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes

BACKGROUND: Sitagliptin has been proven to be effective and safe as add-on to insulin in adult patients with type 2 diabetes and absolute insulin deficiency. Recently, it has been suggested to extend the use of dipeptidyl-peptidase-4 inhibitors to type 1 diabetes. The aim of this study was to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Giampietro, Ottavio, Giampietro, Chiara, Bartola, Luca Della, Masoni, Maria Chiara, Matteucci, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576885/
https://www.ncbi.nlm.nih.gov/pubmed/23439744
http://dx.doi.org/10.2147/DDDT.S38346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576885/
https://www.ncbi.nlm.nih.gov/pubmed/23439744
http://dx.doi.org/10.2147/DDDT.S38346

Ejemplares similares